Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is expected to report second quarter earnings results, before market open, on Monday 3rd August 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.76 per share.
Looking ahead, the full year income are expected at $ 3.71 per share on the revenues of $ 142.45 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 140.00 million ~ $ 140.00 million, where as bottomline are predicted in a range of $ 3.65 ~ $ 3.65 per share
Click Here For More Historical Outlooks Of Ligand Pharmaceuticals Incorporated
Previous Quarter Performance
Ligand Pharmaceuticals Incorporated recorded income for the first quarter of $ 0.89 per share, from the revenue of $ 33.16 million. The quarterly earnings lowered 23.28 percent while revenues shrunk 23.74 percent compared with the same quarter last year.
According to street consensus, LGND was expected to report 1Q20 income of $ 0.66 per share from revenue of $ 26.53 million. The bottom line results beat street analysts by $ 0.23 or 34.85 percent, at the same time, top line results outshined analysts by $ 6.63 million or 24.99 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Ligand Pharmaceuticals Incorporated
Stock Performance
According to the previous trading day, closing price of LGND was $ 117.18, representing a 104.72 % increase from the 52 week low of $ 57.24 and a 8.31 % decrease over the 52 week high of $ 127.80.
The company has a market capital of $ 1.88 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”LGND” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Ligand Pharmaceuticals Incorporated will be hosting a conference call at 8:30 AM eastern time on 3rd August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ligand.com
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The companys partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others.
